<DOC>
	<DOCNO>NCT01407380</DOCNO>
	<brief_summary>This Phase 1 study evaluate safety , pharmacokinetics , pharmacodynamics , clinical effect orally administer PWT33597 mesylate subject advanced malignancy .</brief_summary>
	<brief_title>Study PWT33597 Mesylate Subjects With Advanced Malignancies</brief_title>
	<detailed_description>This multicenter , open-label , non-randomized , dose-escalation study , conduct 2 phase . The Dose Escalation Phase ( 36 patient ) determine MTD PWT33597 mesylate evaluate safety tolerability , PK , PD , preliminary clinical effect ; subsequent Dose Confirmation Phase ( 36 patient ) cohort expansion MTD PWT33597 mesylate . Subjects treat once-daily oral dos PWT33597 consecutive , 28-day cycle . Subjects evaluate regularly safety . Subjects return follow-up visit 28 day completion last dose study drug . Subjects tolerate drug experience progressive disease may continue receive PWT33597 mesylate discretion principal investigator 24 cycle</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1 . Males females ≥18 year age . 2 . Pathologically confirm advanced solid tumor malignant lymphoma standard therapy proven provide clinical benefit exist longer effective . 3 . Eastern Collaborative Oncology Group ( ECOG ) Performance Status ≤1 4 . Evaluable disease , either measurable physical examination image Response Evaluation Criteria Solid Tumors ( RECIST v1.1 ) , criteria International Working Group ( IWG ) Revised Response Criteria Malignant Lymphoma , informative tumor marker ( ) . 5 . Laboratory value screen : Absolute neutrophil count ≥1,500 /mm3 ; Platelets ≥100,000/mm3 ; Total bilirubin ≤1.5 × upper limit normal ( ULN ) ; AST ( SGOT ) ≤2.5 × ULN ; ALT ( SGPT ) ≤2.5 × ULN ; Serum creatinine ≤1.5 mg/dL measure creatinine clearance ≥60 mL/min ; Negative serum betahCG test woman childbearing potential ( defined woman ≤50 year age history amenorrhea ≤12 month prior study entry ) . 6 . Patients primary liver cancer hepatic metastasis eligible enroll , provide , screen , follow criterion meet : Total bilirubin high ULN ; AST ALT ≤5 × ULN ; Severe liver dysfunction ( ChildPugh Class B C ) present ; Patients history esophageal bleed varix sclerosed banded bleeding episode occur prior 6 month . 7 . If history brain metastasis treat radiation therapy , radiation therapy must occur least 6 week prior enrolment metastatic disease must stable since completion . 8 . Willing able provide write Informed Consent comply requirement study . 9 . In addition , subject enrol Dose Confirmation Phase must meet following criterion : For subject solid tumor , measurable disease , use RECIST v1.1 ; For subject malignant lymphoma , least 1 lesion clearly measurable &gt; 1.5cm transverse diameter 2 perpendicular dimension , per criterion International Working Group Revised Response Criteria Malignant Lymphoma ; No prior treatment investigational PI3K , PI3K/mTOR , AKT mTORC1/mTORC2 inhibitor ( prior treatment temsirolimus , everolimus , ridaforolimus allow ) ; For subject colorectal cancer , evidence lack mutation KRAS BRAF , unless otherwise approve sponsor . Tissue block biopsy confirmation PI3K alpha mutation tumor genotyping . Tumor accessible pre posttreatment biopsy cytology ( subset least 5 subject specific tumor type ) . 1 . Any chemotherapy , immunomodulatory drug therapy , antineoplastic hormonal therapy , immunosuppressive therapy , corticosteroid &gt; 20 mg/day prednisone equivalent ( unless administer prevent contrast material reaction radiographic procedure ) , growth factor treatment ( eg , erythropoietin ) within 14 day prior initiation study drug . 2 . Presence acute chronic toxicity prior chemotherapy , exception alopecia peripheral neuropathy , resolve ≤ Grade 1 , determine National Cancer Institute Common Toxicity Criteria Adverse Events ( CTCAE ) v 4.0 3 . Receipt 5 prior regimen cytotoxic chemotherapy unless prior approval grant sponsor . 4 . Radiotherapy within 4 week prior baseline . 5 . Receipt radiotherapy &gt; 25 % bone marrow . 6 . History stem cell allotransplantation . 7 . Major surgery within 28 day prior initiation study drug . 8 . Life expectancy &lt; 12 week . 9 . Active infection require systemic therapy . 10 . Insulinrequiring diabetes mellitus , presence persistent fast blood glucose &gt; 160 mg/dL . 11 . Known human immunodeficiency virus acquire immunodeficiency syndromerelated illness . 12 . Known active hepatitis B C active liver disease ( malignancy ) . 13 . Uncontrolled congestive heart failure ( New York Heart Association Classification 3 4 ) , angina , myocardial infarction , cerebrovascular accident , coronary/peripheral artery bypass graft surgery , transient ischemic attack , pulmonary embolism within 3 month prior initiation study drug . 14 . History ongoing cardiac dysrhythmias require treatment , atrial fibrillation grade , persistent prolongation QTc ( Fridericia ) interval &gt; 450 msec male &gt; 470 msec female . 15 . Previous malignancy , except nonbasalcell carcinoma skin carcinomainsitu uterine cervix , unless tumor treat curative intent 2 year prior study entry . 16 . Concomitant treatment , anticipate use , pharmaceutical herbal agent potent inhibitor inducer cytochrome P450 3A4 enzyme , unless approve sponsor . 17 . Use investigational agent within 4 week baseline . 18 . Pregnant lactate female . 19 . Women childbearing potential , unless agree use dual contraceptive method , opinion Principal Investigator , effective adequate patient 's circumstance study drug 3 month afterward . 20 . Men partner woman childbearing potential , unless agree use effective , dual contraceptive method ( ie , condom , female partner use oral , injectable , barrier method ) study drug 3 month afterward . 21 . Any severe , acute , chronic medical psychiatric condition , laboratory abnormality may increase risk associate study participation study drug administration , may interfere informed consent process and/or compliance requirement study , may interfere interpretation study result , investigator 's opinion , would make patient inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Advanced malignancy</keyword>
	<keyword>solid tumor</keyword>
	<keyword>cancer</keyword>
</DOC>